In summary, our study highlights the landscape of NFE2L2 MUs and Nrf2-activating MUs and their association with various aspects of cancer, including TMB, patient survival, response to ICIs, and the tumor microenvironment. This evidence concerns the gene NFE2L2 and cancer.